Address
20 Park Plaza
Boston, MA 02116
United States of America (the)
Phone
617-744-4400
Website
Sector
Industrials
Industry
Specialty Business Services
Employees
15
First IPO Date
May 23, 2008
| Name | Title | Pay | Year Born |
| John J. Alam | Co-Founder, Chief Executive Officer, President & Director | 952,940 | 1962 |
| Sylvie L. Gregoire | Co-Founder & Director | 40,000 | 1961 |
| Kelly Blackburn | Executive Vice President of Clinical Development | 609,939 | 1964 |
| William Robert Elder | Chief Financial Officer, General Counsel & Corporate Secretary | 643,664 | 1983 |
| Mark A. De Rosch | Executive Vice President of Regulatory, Government Affairs & Program Management | 0 | 1964 |
| Marinus Verwijs | Executive Vice President of Technical Operations | 0 | 1976 |
| Claudia Ordonez | Senior Vice President of Medical Science | 0 | 1966 |
| Matthew Winton | Chief Commercial & Business Officer | 0 | 1978 |
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.